Zephyr AI

Executive Summary

Zephyr AI is a private biotechnology company leveraging advanced machine learning and multi-modal real-world data to accelerate drug discovery and precision medicine in oncology and metabolic diseases. Founded in 2020 and headquartered in McLean, Virginia, the company's platform integrates diverse datasets to identify novel therapeutic targets and biomarkers, de-risk clinical development, and optimize patient selection strategies. By partnering with pharmaceutical organizations, Zephyr AI aims to streamline R&D workflows and transform complex data into actionable insights. While still in a pre-revenue stage, the company has built a robust AI-driven discovery engine that positions it for future collaborations and pipeline advancement.

Upcoming Catalysts (preview)

• Q4 2026Announcement of first major pharma partnership70% success
• Q1 2027In vivo validation data for lead oncology program60% success
• Q3 2026Series B funding round closing80% success